samuelm7
Posted - 13 hours ago
$PFE I believe that the timing of the $GSK lawsuit was deliberately chosen to undermine $PFE investor sentiment as the earnings announcement approaches.
STOCKPICKERTRADER
Posted - 13 hours ago
$PFE with this additional lawsuit from $GSK it feels like the goose is cooked until resolved or some magic discovery comes to the table. Into the shizer...
dloeb
Posted - 14 hours ago
$PFE most likely this new $GSK lawsuit along with the other $MRNA lawsuit remains an overhang for months ahead and likely to pressure this further down in short term. Painful and quite disappointing to see the action that isn't letting up one bit.
taxplanr
Posted - 14 hours ago
$PFE $MRNA $BNTX $GSK how ong do you think the one hit wonders cash stock piles last in the hands of lawyers? https://www.benzinga.com/general/biotech/24/04/38440329/whats-going-on-with-pfizer-stock-on-thursday
Ro_Patel
Posted - 14 hours ago
Let me get this straight - $MRNA is suing $PFE & $BNTX for mRNA patent infringement in a London court & now $GSK is suing the 2 for...mRNA patent infringement in a Delaware court.
TeresaTrades
Posted - 1 day ago
Largest PUT OI decreases $HTZ $XP $QCOM $GSK $LSXMK
DonCorleone77
Posted - 1 day ago
$CVAC $GSK CureVac, GSK terminate Pandemic Preparedness Agreement Due to a rapidly changing epidemiological environment following the end of the COVID-19 pandemic, CureVac and GSK decided to end the Pandemic Preparedness Agreement jointly concluded with the Federal Republic of Germany in April 2022. This decision was made after consultation with the German Federal Ministry of Health and the German Center for Pandemic Vaccines and Therapeutics. The agreement included the provision of production capacity and supply of mRNA-based vaccines in the event of a public health emergency in Germany. Termination will take effect on May 31, 2024, with no further financial obligations. Completion of CureVac's GMP IV manufacturing plant for the production mRNA-based vaccines is unaffected and progressing. Contingent upon regulatory approval, the facility is expected to be certified in the second half of 2024.
Quantumup
Posted - 1 day ago
BTIG raised the price target on $VRNA to $34 was $31/Buy: BTIG caught up w/ Mgmt to review launch preparation and some specific features of the COPD landscape that make the launch of a drug that could reach millions of patients a reasonable undertaking for a Biotech Company: $gsk
StockInvest_us
Posted - 3 days ago
Signal alert: $GSK - Possible Runner https://stockinvest.us/l/5Z5v3ptzFj
TheWinningStock
Posted - 6 days ago
$IBRX <<<---well longs, $tsvt $gsk $crdl we are almost a the finish line, two more business days and the price should top to no less than $15, good luck, see ya in Vegas!..
johnnythehammer
Posted - 1 week ago
$ME Blackrock is in at $3.22ish.
I believe Anne will have to be over $4 a share to have a shot at this …. That doesn’t mean $GSK or others might want $ ME also ….
johnnythehammer
Posted - 1 week ago
$ME Come on $GSK… you gonna let Anne take it from you???
DonCorleone77
Posted - 1 week ago
$GSK GSK announces data from the ZOSTER-049 long-term phase III trial of Shingrix GSK announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with Shingrix. The final trial data demonstrate that RZV maintains efficacy against shingles for more than a decade in adults over 50. The data will be presented at ESCMID Global, European Society of Clinical Microbiology and Infectious Diseases, 2024, formerly known as ECCMID in Barcelona, Spain. The results from ZOSTER-049, an extension from two phase III clinical trials in adults aged 50 and over, include: 79.7% vaccine efficacy in adults aged greater than or equal to50 cumulatively within the period from year six to year 11 after vaccination; 82.0% VE in adults greater than or equal to50 at year 11, showing VE remains high in each year after vaccination; 73.1% VE in adults aged greater than or equal to70 cumulatively from six to 11 years after vaccination showing high VE rates across all age groups. Phil Dormitzer, Senior Vice President, Head of Vaccines R&D, said: "These data go far beyond the typical long-term follow-up period for a trial, tracking the efficacy of vaccination for some participants as they aged into their 70s, 80s and 90s. With the vaccine now included in many national immunisation programmes around the world, these data add to the body of evidence on the extended long-term protection against shingles and provide further confidence to inform public immunisation strategies."
G101SPM
Posted - 1 week ago
#OPTIONACTION Sentiment: The CBOE Put/Call ratio is currently: 0.92, $VIX: (18.31, -0.92, -4.8%). $AMC Apr 3 calls are seeing interest with the underlying stock up 11% (volume: 22.8K, open int: 12.2K, implied vol: ~25%, prev day implied vol: 22%). Co is expected to report earnings early May. $GSK Apr 41 calls (volume: 3490, open int: 60, implied vol: ~26%, prev day implied vol: 24%). Co is expected to report earnings early May. $SB Apr 5 puts (volume: 2060, open int: 0, implied vol: ~64%, prev day implied vol: 44%). Co is expected to report earnings early May. $HBAN Jan25 10 puts (volume: 1620, open int: 20, implied vol: ~39%, prev day implied vol: 36%). Co is confirmed to report earnings Friday before the open.
jarepeo
Posted - 1 week ago
$AUPH It's time for $GSK to step up and BO Aurinia. Then they can offer the Benlysta/Lupkynis combo treatment at a reasonable price.
Quantumup
Posted - 1 week ago
Piper Sandler raised the PT on $VRNA to $36 was $31/Overweight: "VRNA remains one of our 2024 names with what we believe to be the lowest clinical risk and highest PoS (95%) for approval for ensifentrine in COPD:" "We updated our COPD model and increased our PT to $36/share." $gsk
DonCorleone77
Posted - 1 week ago
$GSK GSK meningococcal ABCWY vaccine candidate accepted for FDA review GSK plc announced that the U.S. Food and Drug Administration has accepted for review a Biologics License Application, or BLA, for its 5-in-1 meningococcal ABCWY vaccine candidate. The Prescription Drug User Fee Act, or PDUFA, goal date for a decision by the US FDA on this application is February 14, 2025.
trade_a_lot
Posted - 2 weeks ago
@lordwilmore @crazymoney123 @Draven666 I am hoping that they are working on something. Best options that I can think of:
1. Merge consumer with Ancestry via $BX . Tons of synergies there. Worlds largest DNA database. 2 best brands. Cross sell/ upsell ancestry and health.
2. SPAC out the therapeutics division to get rid of burn and get some cash. Shareholders get shares in new SPAC co
3. JV or sell therapeutics division with $GSK. GSK covers all costs and keeps majority of revenues and pays royalty to $ME along with upfront payment. Exclusivity deal. 4. Options 1 and 3 together at the same time
Any of these will send stock over $1.
StockInvest_us
Posted - 2 weeks ago
Signal alert: $GSK - Oversold Trend Short (Undervalued) https://stockinvest.us/l/1oTRHxENpK
Secret_Options
Posted - 2 weeks ago
$GSK fully allocated.
LVMN_Rocks
Posted - 2 weeks ago
$ABSI $CYDY $GSK $MRK. $ABSI $2.27 Increase since then
Alyrovics
Posted - 2 weeks ago
$GSK opened one of my biggest position in my divi portfolio here today, intending to hold forever-ish. Good luck everyone!
Aigner_Andreas
Posted - 3 weeks ago
TF SELL $GSK at 40.86 : 41.35 BigCap 70% Shp 1.57 S 5.73 N 0.96 RSI 35.39% SRSI 0% ADXR 27.02 #stocks #trading #finance #market
Great_Googly_Moogly
Posted - 3 weeks ago
@Largereach $GSK cured a cancer and their stock is not so great.
Great_Googly_Moogly
Posted - 3 weeks ago
$GSK How does GSK develop a cure for rectal cancer and the stock doesn’t soar? Has anyone heard of Jemperli? It’s revolutionary and rectal cancer is fairly common throughout the world. It’s hard to believe the stock is not doing better than this.
Power2k
Posted - 03/27/24
$VKTX I think these BPs are in a bidding spree now - for a promising and potential best-in-class weight loss drug available in both SubQ and Oral forms, plus a potential best-in-class MASH/NASH drug in the making as well. A combined TAM exceeds 130 billion which is going thru the roof.
$PFE $MRK $GSK $ABBV
Power2k
Posted - 4 weeks ago
$VKTX $PFE $MRK $GSK
Educated_Degenerate
Posted - 4 weeks ago
Been adding some big pharma $PFE $GSK
